ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer
02 mai 2023 01h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s...
ObsEva Annual Report 2022
28 avr. 2023 12h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – April 28, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel...
ObsEva Announces Change of Central Securities Depositary
20 avr. 2023 07h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 20, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing...
ObsEva Announces Change of Central Securities Depositary
20 avr. 2023 01h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 20, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing...
ObsEva Files Year End 2022 Financial Statements
31 mars 2023 16h01 HE
|
ObsEva SA
ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market:...
ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023
15 mars 2023 07h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Progress Towards its Plans to Consolidate Operations in Switzerland: Delisting of OBSV from The Nasdaq Stock Market effective March 23, 2023
15 mars 2023 02h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
13 mars 2023 07h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Update Towards its Strategic Reorganization to Consolidate Operations in Switzerland
13 mars 2023 02h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...
ObsEva Announces Strategic Reorganization to Consolidate Operations in Switzerland
24 févr. 2023 07h00 HE
|
ObsEva SA
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and...